3 TSX Penny Stocks With Market Caps Under CA$200M
As the Canadian market experiences moderate growth, with the TSX up about 3% this year, investors are keenly observing economic indicators such as inflation and interest rates which have shown signs of stabilization. In this context, penny stocks—typically smaller or newer companies—offer intriguing opportunities for those seeking growth at lower price points. Despite being an outdated term, these stocks can present significant potential when backed by strong financials and sound fundamentals.
Name
Share Price
Market Cap
Financial Health Rating
Alvopetro Energy (TSXV:ALV)
CA$4.83
CA$176.58M
★★★★★★
Mandalay Resources (TSX:MND)
CA$4.83
CA$453.58M
★★★★★★
Findev (TSXV:FDI)
CA$0.52
CA$14.9M
★★★★★★
PetroTal (TSX:TAL)
CA$0.69
CA$632.31M
★★★★★★
NamSys (TSXV:CTZ)
CA$1.20
CA$32.24M
★★★★★★
East West Petroleum (TSXV:EW)
CA$0.045
CA$4.07M
★★★★★★
Orezone Gold (TSX:ORE)
CA$0.90
CA$416.19M
★★★★★☆
New Gold (TSX:NGD)
CA$4.02
CA$3.18B
★★★★★☆
Foraco International (TSX:FAR)
CA$2.00
CA$197.39M
★★★★★☆
DIRTT Environmental Solutions (TSX:DRT)
CA$1.08
CA$208.88M
★★★★☆☆
Click here to see the full list of 934 stocks from our TSX Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Dundee Corporation is a publicly owned investment manager with a market cap of CA$178.83 million.
Operations: The company generates revenue primarily from its Mining Services segment, which accounts for CA$1.73 million, and Corporate and Others segment, contributing CA$4.22 million.
Market Cap: CA$178.83M
Dundee Corporation, with a market cap of CA$178.83 million, has recently turned profitable after several years of growth, achieving an annual earnings increase of 44.6% over the past five years. Despite having limited revenue (CA$5 million), its low price-to-earnings ratio (2.8x) suggests it might be undervalued compared to the broader Canadian market. The company benefits from experienced management and board teams and boasts a strong financial position with short-term assets significantly exceeding both short-term and long-term liabilities. However, challenges remain as operating cash flow is negative, impacting debt coverage capabilities.
Dive into the specifics of Dundee here with our thorough balance sheet health report.
Review our historical performance report to gain insights into Dundee's track record.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Payfare Inc. is a financial technology company offering instant payout and digital banking solutions to gig economy workers in Canada, the United States, and Mexico, with a market cap of CA$192.67 million.
Operations: The company generates revenue from its data processing services, amounting to CA$216.87 million.
Market Cap: CA$192.67M
Payfare Inc., a financial technology company, has shown significant earnings growth of 74.3% over the past year, surpassing the industry average. It boasts a high return on equity of 22.2% and maintains a debt-free balance sheet with short-term assets exceeding liabilities. Despite its volatile share price, Payfare's profitability has improved with net profit margins rising to 8.9%. The company is currently undergoing an acquisition by Fiserv's affiliate at CA$4 per share, offering a substantial premium to shareholders despite some opposition claiming undervaluation concerns. Shareholders have approved this transaction at the recent special meeting.
Take a closer look at Payfare's potential here in our financial health report.
Review our growth performance report to gain insights into Payfare's future.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Finlay Minerals Ltd. is engaged in the acquisition and exploration of base and precious metal deposits in northern British Columbia, Canada, with a market cap of CA$19.62 million.
Operations: Finlay Minerals Ltd. has not reported any revenue segments.
Market Cap: CA$19.62M
Finlay Minerals Ltd., a pre-revenue exploration company, focuses on its PIL and ATTY properties in British Columbia's Toodoggone district. Recent developments include identifying multiple porphyry and epithermal targets, with significant mineralization at the PIL South target. Despite its unprofitable status and negative return on equity, Finlay remains debt-free with a stable cash runway exceeding three years. The company's short-term assets surpass liabilities, although long-term liabilities remain uncovered. With an experienced management team and board, Finlay plans further exploration in 2025 to delineate drill targets around promising discoveries near property boundaries.
Unlock comprehensive insights into our analysis of Finlay Minerals stock in this financial health report.
Understand Finlay Minerals' track record by examining our performance history report.
Discover the full array of 934 TSX Penny Stocks right here.
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Jump on the AI train with fast growing tech companies forging a new era of innovation.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TSX:DC.A TSX:PAY and TSXV:FYL.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
37 minutes ago
- Politico
Should we stay or should we go
Presented by The Canadian Medical Association Send tips | Subscribe here | Email Canada Playbook | Follow Politico Canada Thanks for reading Canada Playbook. It's Friday! In today's edition: → DOMINIC LEBLANC is working the phones. → MARK CARNEY and others beg to differ with criticism over First Nations. → The House gears up to gear down. Trade war COUNTERMOVES — Canada-U.S. Trade Minister DOMINIC LEBLANC will hold a virtual meeting today with United States Trade Representative JAMIESON GREER. On the agenda: Working the deal. 'The fact that there's now a deadline set by the two leaders, I think, has focused the conversation,' he said Thursday, standing next to Prime Minister MARK CARNEY at a press conference on Parliament Hill. — Vibe check: LeBlanc said he's optimistic negotiations will advance toward a new security and economic deal. — Brace for impact: That was Carney's message Thursday when he announced that Canada is prepared to levy additional counter-tariffs on U.S. aluminum and steel imports — but not before July 21 — after the 30-day deadline has come and gone. — Cold steel welcome: After scrapping a Thursday presser, CATHERINE COBDEN, president of the Canadian Steel Producers Association, and MARTY WARREN, the Canada director of United Steelworkers union, issued a joint statement panning Carney's announcement. 'We will continue to review the details of the measures and work constructively with the federal government to get a plan that works for Canadian steel producers and the thousands of workers that make up our sector,' they said. — Working the phones: Carney said he'll speak with provincial and territorial premiers today 'to discuss this response and our broader coordination.' That conversation is scheduled for noon. The PM also said he 'frequently' communicates with President DONALD TRUMP. — Paging Premier Ford: When the PM returned to Ottawa from the G7 in Kananaskis, one of the first people he called was DOUG FORD. The Ontario premier had been urging Carney to limit how much steel can be imported into Canada from non-free trade agreement countries, a source familiar with the discussions told Playbook. Playbook granted anonymity to the individual as they weren't authorized to discuss internal matters. The PM and the premier also remain in regular contact. And Ford continues urge Carney to retaliate against the U.S. after it doubled tariffs on steel and aluminum imports to 50 percent earlier this month. Canada has 25 percent counter-tariffs in place on U.S. metals. 'If the president doesn't come to the table, I'll give [Carney] my full support on full-out tariffs of 50 percent on steel,' Ford told reporters in Toronto on Thursday. — After Trump's hike: Ford texted U.S. Commerce Secretary HOWARD LUTNICK: 'I thought no surprises.' The message got Lutnick's attention, though details of their exchange were not disclosed to Playbook. Ontario does not have a formal role in negotiations, but Ford keeps in contact with Lutnick when White House decisions touch on Ontario workers and businesses. — Wait, negotiate, react: Canada is so far holding off. Ultimately countermeasures will depend on what Canada and the U.S. achieve in negotiations. 'We'll continue these negotiations, of course, in good faith,' Carney said. 'In parallel, we must reinforce our strength at home and safeguard Canadian workers and businesses from the unjust U.S. tariffs that exist at present.' — First step, not a final fix: Industry Minister MÉLANIE JOLY later turned up on CBC's 'Power & Politics' with DAVID COCHRANE to reassure anxious workers. 'The most important thing is, ultimately, people having a job and their family being able to, you know — like we say in French — put butter and bread on the table,' she said. 'That's why this is a first response to the steel-aluminum crisis.' WHO'S UP, WHO'S DOWN Up: 'The bro-thing.' TONDA MACCHARLES notes in the Star that the PM has yet to invite many women into his top inner governing circle. 'Does it matter? Time will tell.' Down: The G7 — or is that 6? DRIVING THE DAY BBQ READY — The House is expected to rise today. — But first: The government must pass Bill C-5, controversial legislation that the Liberals promise will use 'nation-building projects' to transform Canada into an economic powerhouse. Lawmakers must sit until the bill passes the House. MPs need to vote on the amendments made to the bill during Thursday's marathon transport committee meeting. Then the bill is expected to pass its third reading — the final stage, which sends the bill to the Senate. — Easy peasy: It shouldn't take too long. The Liberal minority government has forged an unlikely bond with the Conservative caucus to push this major legislation through the House by Canada Day — a promise Carney made on the campaign trail. The Tories even supported Liberal efforts to expedite Bill C-5. If all goes as expected today, it will have taken just 14 days for the bill to be introduced and passed by the House of Commons. — Meanwhile in the Senate: The Red Chamber is prepared to sit until June 27 in order to get the bill passed by July 1. We'll be there. THE ROOMS THAT MATTER — 12 p.m. The PM will host a virtual First Ministers' Meeting. — 2 p.m. Canada's Taxpayers' Ombudsperson FRANÇOIS BOILEAU will release his 2024–2025 annual report, containing two recommendations to improve the Canada Revenue Agency. ON THE HILL BILL C-5 BACKLASH — The PM is pushing back at critics who say his big bill on building energy projects fast — the one speeding through Parliament — is railroading First Nations. At his Thursday presser, Carney dismissed warnings that a speedy passage of Bill C-5 will ignite a summer of discontent across Canada. Former Liberal Justice Minister JODY WILSON-RAYBOULD is among those urging First Nations to draw a 'line in the sand.' Carney said Section 35 of the Canadian Constitution, is reflected in the bill, and guarantees 'free, prior and informed consent' and 'full consultations with Indigenous peoples to define what is a nation-building project.' He said the bill would ensure full economic participation by Indigenous groups. — Other voices: STEVE MACKINNON, the Liberal Government House Leader, said C5 would ensure the full participation of Indigenous groups, many of which fully support the bill and the economic benefits new projects will bring to their communities. 'What I don't hear in the questioning is those Indigenous communities in this country, Indigenous Nations that wish to participate economically — whether in equity stakes or with job creation in these major national projects,' MacKinnon said Thursday. 'They exist all over the country and they deserve to have their voices heard.' — Case in point: The First Nations Major Projects Coalition includes more than 170 Indigenous groups with an equity stake in 18 projects valued at C$45 billion. When the bill was introduced June 6, the group issued a statement emphasizing the continued imperative for First Nations to be 'true partners at every step of the process' in national interest projects. Chief SHARLEEN GALE of the Fort Nelson First Nation and the chair of the FNMPC's board of directors said in a June 6 statement that she understands the need to move fast. 'History has shown us that speed without partnership leads to delay — not progress. This legislation could be a turning point if it is designed and administered in true partnership with First Nations.' — Over here: Playbook asked FNMPC to speak with Gale, but we haven't heard back. We're still interested, so contact us here. — About time: HEATHER EXNER-PIROT, the director of Macdonald-Laurier Institute's energy and resources program, told MPs on Wednesday night that although the bill is not perfect, it is long overdue. She said it is 'refreshing' that the Liberals and Conservatives have banded together to support it. 'For 10 years, much of the resource sector in this country has been in fight-or-flight mode, but the past few weeks, I've been hearing optimism and bullishness from Prairie premiers and energy CEOs,' she said. 'They believe this government actually intends to build some infrastructure and position Canada to be an energy superpower.' Want more POLITICO? Download our mobile app to save stories, get notifications on U.S.-Canada relations, and more. In iOS or Android . MORNING MUST-CLICKS — 'The Carney-Sabia combo will be felt profoundly and fast,' KATHRYN MAY writes in The Functionary. She adds: 'A senior shuffle is expected any day, and departments are already being asked to map out spending-cut scenarios for a looming expenditure review.' — Foreign Affairs Minister ANITA ANAND spoke with CP's DYLAN ROBERTSON ahead of next week's trip to Europe, which includes the NATO summit. — From CATHERINE LÉVESQUE at the National Post: Doug Ford apologizes to Ontario First Nations for his 'passionate' comments. — From the Star's NICHOLAS KEUNG: Carney government clarifies Canadian border bill's asylum changes as critics call for complete withdrawal. — ALEX BOUTILIER of Global News writes on JAGMEET SINGH's life under RCMP protection. — And the Globe's CHRIS HANNAY reports: 23andMe probe highlights Privacy Commissioner's lack of powers compared to U.K counterpart. PLAYBOOKERS Birthdays: HBD to PHILIP LAWRENCE and to public affairs pro ROMEO TELLO. On Sunday: Former MPs WAYNE EASTER and BEV SHIPLEY. Spotted: Former PMs JEAN CHRÉTIEN and STEPHEN HARPER having a convivial lunch at the Rideau Club. And in QP, MARK CARNEY, accidentally calling the speaker 'Mr. Prime Minister.' Noted: Finance Minister FRANÇOIS-PHILIPPE CHAMPAGNE said Thursday that Canada is 'going ahead' with the digital services tax. Canada's competition watchdog is advising Ottawa that Canadians want more competition in a domestic airline industry dominated by Air Canada and WestJet. The Competition Bureau shared 10 recommendations to the government — including one that would allow more foreign investment in Canadian airlines. Lobby watch: Grain Growers of Canada met Thursday with Conservative MP KYLE SEEBACK. They also met with Secretary of State of Rural Development BUCKLEY BELANGER. … LEAH YOUNG of National Marine Manufacturers Association Canada met with Conservative MP TONY BALDINELLI, 'to advocate for tariff remissions on recreational marine products impacted by cross-border duties.' Send Playbookers tips to canadaplaybook@ PROZONE For Pro subscribers, our latest policy newsletter from MIKE BLANCHFIELD and SUE ALLAN: Carney puts Trump on notice. In other Pro headlines: — How Trump's cuts could weaken wildfire prevention. — Chamber memo forecasts 'meaningfully higher' Trump tariffs. — Canada to adjust US metal tariffs on July 21. — Trump to open over 80 percent of Alaskan reserve to oil leasing. — GOP frustrated but unwilling to act on Trump's TikTok extension. Trivia Thursday's answer: ANDRÉE CHAMPAGNE. Props to SEAN SUNDERLAND, LISA HALEY, MALCOLM MCKAY, SHEILA GERVAIS, JOHN PEPPER, ROBERT MCDOUGALL, FELIX BERNIER, JUSTIN DE BEAUCAMP, NANCI WAUGH, ELIZABETH BURN, HUGUES THEORET, STEVEN HOGUE, SCOTT MCCORD, RAY DEL BIANCO, LYNE FORTIN-MARCOTTE, SEAN P. WEBSTER, PATRICK ST-JACQUES and MARCEL MARCOTTE. Friday's question: Who signed the proclamation requesting that Canadians celebrate July 1? Hint: It happened on this date in history. Answer to canadaplaybook@ Writing Monday's Playbook: MIKE BLANCHFIELD
Business Upturn
an hour ago
- Business Upturn
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
By GlobeNewswire Published on June 20, 2025, 11:30 IST TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative. NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up. HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants. Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2 .' NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs. Omnibus Plan Approval The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs'). The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date. The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate. Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider. RSU Grants In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')). About NurExone NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For additional information and a brief interview, please watch Who is NurExone?, visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034 Email: [email protected] Dr. Eva Reuter Investor Relations – GermanyPhone: +49-69-1532-5857 Email: [email protected] Allele Capital Partners Investor Relations – +1 978-857-5075 Email: [email protected] FORWARD-LOOKING STATEMENTS This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. i Spinal cord injury, Glaucoma 1 2 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Boston Globe
3 hours ago
- Boston Globe
Canadian tariffs on US steel and aluminum could rise depending on trade talks, Carney says
He added: 'In parallel, we must reinforce our strength at home – and safeguard Canadian workers and businesses from the unjust U.S. tariffs. That's why today we are announcing Canada will be introducing a series of countermeasures to protect Canadian steel and aluminum workers and producers. 'First, Canada will adjust its existing counter-tariffs on U.S. steel and aluminum products on July 21 to levels consistent with progress made in the broader trading agreement with the United States.' Carney said Trump's trade war is running the risk of a global recession. Advertisement 'The world is in the middle of a trade war and several wars, actual wars, including wars that can have quite significant implications for commodity prices and global growth,' said Carney, who led the central banks of both Canada and the United Kingdom. Trump has imposed 50% tariffs on steel and aluminum as well as 25% tariffs on autos. Trump is also charging a 10% tax on imports from most countries, though he could raise rates on July 9, after the 90-day negotiating period set by him would expire. Canada and Mexico face separate tariffs of as much as 25% that Trump put into place under the auspices of stopping fentanyl smuggling, through some products are still protected under the 2020 U.S.-Mexico-Canada Agreement signed during Trump's first term. Advertisement Canada is the largest foreign supplier of steel, aluminum and uranium to the U.S. and has 34 critical minerals and metals that the Pentagon is eager for. Nearly $3.6 billion Canadian dollars ($2.6 billion) worth of goods and services cross the border each day. Canada is the top export destination for 36 U.S. states. 'We need to stabilize the trading relationship with the United States. We need to have ready access to U.S. markets,' Carney said. Trump announced with British Prime Minister Keir Starmer that they had signed a trade framework Monday that was previously announced in May. The trade framework included quotas to protect against some tariffs, but the 10% baseline would largely remain as the Trump administration is banking on tariff revenues to help cover the cost of its income tax cuts. Carney didn't say if he would sign a deal with the U.S. if any tariffs remain in place on Canada. 'This a negotiation, and it is better for the Americans, and of course for Canada, to have true free trade between our countries, particularly in the steel, aluminum and auto sectors,' he said.
